Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Given Average Recommendation of “Buy” by Analysts

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) has been given a consensus recommendation of “Buy” by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, two have given a buy recommendation and two have given a strong buy recommendation to the company.

Several analysts recently commented on CURLF shares. Zacks Research upgraded shares of Curaleaf from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Atb Cap Markets upgraded shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 2nd. Alliance Global Partners reissued a “buy” rating on shares of Curaleaf in a research note on Monday, December 22nd. Canaccord Genuity Group raised Curaleaf to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, ATB Capital raised Curaleaf to an “outperform” rating in a report on Tuesday, December 2nd.

Curaleaf Stock Up 6.0%

CURLF opened at $2.30 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.47 and a quick ratio of 0.71. Curaleaf has a 12 month low of $0.68 and a 12 month high of $5.05. The stock has a market capitalization of $1.56 billion, a P/E ratio of -7.19 and a beta of 0.74. The business has a 50 day simple moving average of $2.70 and a 200-day simple moving average of $2.61.

Curaleaf (OTCMKTS:CURLF) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. On average, equities analysts anticipate that Curaleaf will post -0.25 earnings per share for the current fiscal year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.